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Acute esophageal variceal hemorrhage (AEVH) is a
devastating complication of portal hypertension. Eval-
uation of the natural history of AEVH showed that it
is associated with a mortality rate of 40%, and a high
incidence of early rebleeding of 30–50% among the
survivors [1]. The factors responsible for AEVH are
not well known. Portal pressure, variceal pressure,
and the tension of the esophageal variceal wall have
been demonstrated to be associated with AEVH.
Hepatic venous pressure gradient (HVPG) >12 mmHg
is noted to be a requisite in patients with variceal
rupture [2]. Poor hepatic reserve and the appearance
numerous red color signs on the large varices are
important factors predicting AEVH [3]. In Taiwan,
for unknown reasons, gastroenterologists have noted
that the incidence of AEVH is higher in the winter
season.
There are a handful of treatment modalities avail-
able for the management of AEVH. Vasoconstrictors
and endoscopic therapy are the most frequently used
tools to control AEVH. Appropriate use of these mo-
dalities should improve the survival of patients with
AEVH. This article reviewed the relevant literature and
summarized the limitations and advantages of the
various treatment modalities used for AEVH; and to
provide practical guidance for clinicians to manage this
severe medical emergency.
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Acute esophageal variceal hemorrhage (AEVH) is a severe complication of portal hypertension.
Its management has rapidly evolved in recent years. Traditional methods included vasoconstric-
tor and balloon tamponade. Vasoconstrictors were shown to control approximately 80% of the
bleeding episodes and are generally used as a first-line therapy. Following the use of vasocon-
strictors, endoscopic therapy is often used to arrest the bleeding varices and prevent early
rebleeding. A meta-analysis showed that the combination of vasoconstrictor and endoscopic
therapy is superior to endoscopic therapy alone for controlling AEVH. Balloon tamponade may
be used to achieve temporary control of the hemorrhage in case of severe bleeding. A transjugu-
lar intrahepatic portosystemic stent shunt may be needed in patients with refractory acute
variceal hemorrhage. Surgical intervention is now widely contraindicated during acute variceal
hemorrhage, except for patients with good liver reserve. Conversely, apart from the control of
acute variceal hemorrhage, prophylactic antibiotics were shown to be helpful in the prevention of
bacterial infection and to prevent early variceal rebleeding. With the introduction of new treat-
ment modalities and the measures taken to manage patients with AEVH, the mortality due to
AEVH has significantly decreased in recent years.
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FIRST AID FOR AEVH
Upper gastrointestinal hemorrhage originating from
gastroesophageal varices generally bleeds more pro-
fusely than other non-variceal lesions. Episodes of
AEVH may present with either hematemesis and/or
tarry stool, hematochezia. The presence of bloody
vomitus may represent either more profuse bleeding
or bleeding from a source not far from the mouth,
such as the esophagus. Before endoscopic confirmation
of the source of bleeding, any history of portal hyper-
tension or the use of nonsteroidal anti-inflammatory
drugs should be evaluated and signs of portal hyper-
tension should be ascertained. Tracing the history of
portal hypertension can be helpful to guide decision-
making for first aid because endoscopists are not
always available.
Nasogastric tube insertion and water irrigation is
necessary to remove fine material, blood clots, or fresh
blood for patients with acute upper gastrointestinal
bleeding. The use of a nasogastric tube does not nor-
mally increase the risk of further esophageal variceal
rupture. Nasogastric tube irrigation can be used to
assess the severity of hemorrhage, the amount of blood
loss, and to aspirate bloody materials to prevent the
occurrence of hepatic encephalopathy in patients with
portal hypertension. Moreover, application of naso-
gastric irrigation will provide a clear visual field dur-
ing endoscopy, which is helpful for endoscopists to
accurately identify the bleeding esophageal varices.
A clear visual field is also required to differentiate blee-
ding originating from gastric varices or esophageal
varices in patients with concomitant gastroesophageal
varices. Blood transfusion is usually required in most
patients with AEVH. The amount of blood required
should be carefully evaluated. Most experts suggest
that hemoglobin should be kept at around 8 g/dL
and hematocrit at around 30% [4]. This is necessary
to avoid over-transfusion, which may accentuate the
disturbances in portal hypertension that lead to con-
tinual hemorrhage [5]. Overzealous transfusion may
also induce pulmonary edema and further worsen-
ing of hemodynamic instability. In contrast, patients
with AEVH are more likely to show impaired renal
function compared with patients with non-variceal
bleeding, partly due to the frequent association of
AEVH with shock status. Thus, careful monitoring
and evaluation of the necessity and rapidity of blood
transfusion in patients with AEVH is mandatory.
Endotracheal tube insertion to prevent aspiration
and the use of sedatives may be required in some
critical cases, particularly alcoholic patients with
hepatic encephalopathy or withdrawal symptoms.
However, the endotracheal tube should be removed
once the endoscopic therapy has been performed and
the vital signs have stabilized.
Because of the critical situations and poor out-
comes associated with AEVH, hepatology experts usu-
ally recommend that patients with AEVH are managed
in intensive care units. However, in our own experi-
ence, only a small proportion of AEVH patients in
critical situations such as torrential hemorrhage, im-
pending hepatic failure or sepsis actually require care
at intensive care units.
The outcomes of AEVH have been demonstrated to
depend on the severity of cirrhosis, as reflected by the
Child-Pugh class, active bleeding during endoscopy
[6], HVPG > 20 mmHg [7], the presence of bacterial
infection and impaired renal function [8].
Vasoconstrictors
Vasoconstrictors are often used as the first-line therapy
for AEVH because they are usually safe and easy to ap-
ply. Vasopressin was the first vasoconstrictor approved
approximately 20 years ago and had been widely
used to arrest AEVH. The mechanisms by which vaso-
pressin modulates hemostasis involve direct stimula-
tion of vasoconstriction of splanchnic vessels with a
reduced portal pressure, and on the esophageal wall
and its vessels, to reduce blood flow. The efficacy of va-
sopressin in arresting AEVH varies widely, and was
reported to range from 9% to 93% [9–14]. Pooled esti-
mates of the trials have yield overall values of about
60–75% [15]. Before the era of the newer vasoconstric-
tors, vasopressin was generally shown to be benefi-
cial in controlling AEVH. However, vasopressin is
associated with a high frequency of complications
such as hypertension, hyponatremia, severe arrhyth-
mia, abdominal cramp, coronary artery spasm or myo-
cardial infarction, and skin, intestinal or scrotal
ischemia, and has limited its usage and offset its
effectiveness [9–14,16]. The addition of nitroglycerin
to vasopressin was shown to enhance the efficacy of
hemostasis and reduce the incidence of associated
complications [11,12]. Moreover, hyposensitivity to
vasopressin during acute variceal bleeding, particu-
larly during shock, was noted among cirrhotic patients
[17]. After the discovery of newer vasoconstrictors,
vasopressin has almost completely been replaced by
other drugs in the treatment of AEVH.
Terlipressin is an analog of vasopressin, but is
slowly metabolized to vasopressin and is released into
the circulation upon administration. Thus, terlipressin
has advantages such as a longer half-life (1.5 hours)
and a lower frequency of complications. Terlipressin is
generally administered intravenously with a 2-mg
bolus loading dose, followed by 1–2 mg every 4 or 6
hours. Nitroglycerin can also be administered in com-
bination with terlipressin to reduce the occurrence
of complications. The hemostatic rate for terlipressin
was reported to range from 19% to 80% [18–22]. The
hemostatic effect of terlipressin appeared to be lower
in Chinese patients than in Caucasian patients. How-
ever, because these studies were not compared head-
to-head, we do not know whether ethnicity is
responsible for the differences in efficacy. Terlipressin
was usually administered at higher doses (i.e. 2 mg
rather than 1 mg) and at a higher frequency (i.e. at 
intervals of 4 hours rather than 6 hours) in the trials
carried out in Western countries. This may account for
the difference between studies. However, Chang et al
showed that the hemostatic rates were similar between
patients receiving high-dose (2 mg) and low-dose
(1 mg) terlipressin (53% vs. 48%, respectively) [22]. It
has been suggested that terlipressin can be adminis-
tered at a dose of 1mg every 4 or 6 hours once the acute
bleeding has been controlled [23]. Until now, terli-
pressin was the only vasoconstrictor shown to improve
the survival of patients with AEVH [20]. However, be-
cause that study was industry sponsored and terli-
pressin was the only vasoconstrictor that has been
tested in an ambulance setting, it is unknown whether
terlipressin remains superior when other vasoconstric-
tors such as somatostatin are compared under similar
circumstances. A meta-analysis showed that, com-
pared with placebo, terlipressin reduced rates of mor-
tality and failure to achieve hemostasis [21]. Since
terlipressin is a powerful vasoconstrictor, it could be a
first choice for patients with AEVH presenting with
hypotension. Moreover, terlipressin was reported to be
beneficial in the treatment of hepatorenal syndrome
[24]. Consequently, terlipressin could be considered for
patients presenting with AEVH and renal impairment,
and potentially those with hepatorenal syndrome.
However, terlipressin is contraindicated for patients
with coronary artery disease, peripheral vascular dis-
eases or profound shock. Although the complications
of terlipressin are similar to those of vasopressin, its
incidence and severity are significantly reduced. The
most common adverse events associated with terli-
pressin include hypertension, bradycardia and abdom-
inal pain, and range from 10% to 20% [25,26].
Somatostatin is naturally synthesized by the body
and can be commercially produced for clinical use. 
It has a very short half-life, only 3 minutes, compared
with other vasoconstrictors. Thus, somatostatin should
be administered by continuous infusion, usually 3 mg
every 12 hours. However, the mechanisms of hemo-
stasis by somatostatin are not easily understood. The
postulated mechanisms include the inhibition of
glucagon, a weak direct action on esophageal varices,
and reduction of postprandial, or post-hemorrhage
splanchnic hyperemia [27]. The efficacy of somato-
statin for AEVH arrest was around 84%, with early
rebleeding rates of around 20–30%, similar to terli-
pressin [25,28–30]. The reduction in portal pressure
was more pronounced when somatostatin was ad-
ministered at a dose of 500 μg/hr than 250 μg/hr [31].
A controlled study conducted in Spain showed that a
high dose of somatostatin (500 μg/hr) was superior to
a low dose of somatostatin (250 μg/hr) for the control
of active variceal hemorrhage, whereas both doses
had similar hemostatic rates in patients without active
hemorrhage during endoscopy [32]. The complica-
tions of somatostatin are not common and are gener-
ally modest. The most common adverse effects include
hyperglycemia, nausea/vomiting, bradycardia, hyper-
tension and diarrhea [25,26]. Hyperglycemic hyper-
osmolarity nonketotic coma was also encountered in
our study, although this was rare [26].
Octreotide is an analog of somatostatin with a half-
life of approximately 2 hours. Octreotide could be
administered either intravenously or subcutaneously.
The recommended dose of octreotide is 25–50μg/hr.
Octreotide was shown to prevent postprandial hyper-
emia and reduced portal pressure [33], but the hemo-
dynamic effect of octreotide on the reduction of portal
pressure is controversial [34]. Although the half-life
of octreotide is prolonged, rapid desensitization was
noted during hemodynamic studies, and the lowering
of portal pressure was found to last for just a few min-
utes [35,36]. Theoretically, the transient hemodynamic
effect may hinder its efficacy; however, the majority
of studies showed that octreotide is as effective as
other vasoactive drugs for AEVH hemostasis [37–39].
The complications of octreotide are similar to those 
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of somatostatin. Although a meta-analysis has shown
that octreotide compares favorably with other va-
soconstrictors [40], European scholars still regard
octreotide as a drug that requires more studies with
positive results [41]. Conversely, octreotide is widely
adopted in the United States of America to control
AEVH.
It is now widely believed that vasoconstrictors
should be administered on the suspicion of an AEVH
episode. However, the issue of how long the vaso-
constrictors should be administered is less clear [29].
Nowadays, vasoconstrictors are used to arrest acute
hemorrhage and to prevent early variceal bleeding
[23,26]. Some hepatologists have suggested using
vasoactive drugs for 5 days during AEVH to reduce
episodes of early rebleeding [42]. More studies are
needed to evaluate cost-effectiveness and the optimal
duration of administration.
Balloon tamponade
Balloon tamponade arrests AEVH by a direct tampon-
ade effect. Two types of balloon have been adopted,
namely the Sengstaken-Blakemore (SB) tube and the
Linton-Nachlas (LN) tube. The gastric balloon in the
SB tube can only be inflated with 100–200 mL of air or
water, whereas the LN tube may be inflated with up
to 600 mL of water. The pressure of the esophageal
balloon may be increased to 30–40 mmHg. The use of
a higher pressure may achieve a greater hemostatic
effect; however, this may increase the risk of compli-
cations [43]. The optimal duration of balloon tam-
ponade is believed to be around 12–24 hours. It seems
likely that shorter duration of balloon tamponade is
better if hemostasis is quickly achieved. The effec-
tiveness of stopping hemorrhage by balloon tam-
ponade is around 80–94% [44–46]. When bleeding
occurs from esophageal varices, permanent hemo-
stasis was obtained more frequently with the SB tube
than with the LN tube (30%). In bleeding gastric
varices, the SB tube generally failed, whereas perma-
nent hemostasis may be obtained with the LN tube 
in 50% of cases [44]. However, the use of balloon 
tamponade is very unpleasant for the patients and
the rebleeding rate is about 50% after the balloon 
is deflated. Thus, balloon tamponade should be re-
served to patients with massive variceal hemorrhage,
which cannot be arrested by vasoconstrictors or en-
doscopic therapy, or when endoscopists are unavail-
able for emergency endoscopic therapy. The rate of
complications (i.e. nasal alar necrosis, esophageal
ulcers, esophageal rupture, airway obstruction and
aspiration pneumonia) with balloon tamponade is ap-
proximately 15%, and 6% of complications were fatal
[46]. Because of the potential risks, the balloon tam-
ponade should only be inserted in patients with en-
doscopic confirmation of the AEVH and some experts
suggest that it should be only performed in intensive
care unit. Once the balloon tamponade is removed,
endoscopic therapy should be performed to check for
and prevent early rebleeding as soon as possible in
patients who have not yet been treated with endo-
scopic therapy.
Timing of endoscopy
It is generally agreed that cirrhotic patients suffering
from acute upper gastrointestinal hemorrhage should
receive endoscopy to confirm the bleeding source.
However, the most appropriate timing for performing
the endoscopic examinations is less clear. For patients
with AEVH, a wide range of critical situations may
be encountered. If patients present with stable vital
signs and nasogastric irrigation reveals fine material
rather than fresh blood, endoscopic examinations may
not be urgently required. These patients can be man-
aged with vasoconstrictors while at the emergency
room [29] and receive endoscopic examination by
endoscopists at a convenient time. However, some
patients may bleed constantly during this time. For
patients with rapid bleeding on presentation, it is un-
known whether emergency endoscopy and endo-
scopic therapy within a very short period of time
after presentation can improve the outcome. In such
critical situations, it is usually very difficult to perform
emergency endoscopy. The latest Baveno Consensus
of portal hypertension suggested that endoscopy
should be performed within 12 hours for patients
with AEVH [45].
Some studies have compared emergency endo-
scopic therapy and vasoconstrictor therapy in AEVH
and found that vasoconstrictor was as effective as
endoscopic injection sclerotherapy (EIS) for control-
ling bleeding, but with fewer complications [46–50].
Thus, it was claimed that vasoconstrictor can replace
EIS as the first-line therapy for AEVH [51]. However,
a study by our colleagues showed that emergency
endoscopic variceal ligation (EVL) is superior to
somatostatin infusion for 48 hours to control AEVH
without increased risk of complications [30]. Our
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study suggested that EVL should be performed within
24 hours of AEVH.30
Incidence of active esophageal variceal
hemorrhage during endoscopy
Active esophageal variceal hemorrhage during endo-
scopy is a significant challenge for endoscopists.
Unstable vital signs may be encountered and the pro-
cedure may be hazardous if the blood transfusion does
not correct shock status and is associated with pro-
found hypoxemia. Profuse blood in the esophagus
may hinder the identification of the sites of bleeding
and increases the likelihood of endoscopic hemostasis
failure. Fortunately, the incidence of active variceal
hemorrhage during endoscopy is not excessively
high. It is generally believed that approximately one-
third of cases with portal hypertensive bleeding pre-
sented as active variceal bleeding during endoscopy,
one-third had varices that had already stopped bleed-
ing during endoscopy and the other one-third had
bleeding from other lesions [54]. In fact, the incidence
of active variceal bleeding during endoscopy varied
greatly between studies and was reported to range
from 10% to 100% [6,50,55–59]. One of several reasons
for this disparity is that some studies considered
acute and active esophageal variceal hemorrhage inter-
changeably. Variation in disease severity, the interval
from time zero to the performance of endoscopic exam-
ination and prior use of a balloon tamponade or vaso-
constrictors may influence the incidence of active
esophageal variceal hemorrhage during endoscopy. In
our own experience, active esophageal variceal hem-
orrhage during endoscopy accounts for about 10% of
all cases AEVH in recent years [6,26]. It should be
noted that patients with unstable vital signs should
not receive endoscopic examination. If patients with
signs of active upper gastrointestinal hemorrhage
require endoscopic examination, the endoscopists
should be very experienced and blood transfusion
and oximetry monitoring during the procedure are
mandatory.
Conversely, endoscopic diagnosis of AEVH may
also pose a challenge for inexperienced endoscopists
when the varices are not actively bleeding. Inex-
perienced endoscopists should be familiar with the
criteria of acute esophageal variceal hemorrhage.
Stigmata of recent variceal hemorrhage such as white
nipple signs or hematocystic spots should be sought
and treated as quickly as possible in cases of AEVH.
Endoscopic treatment of the bleeding sites of varices
can usually achieve satisfactory results [26].
ENDOSCOPIC THERAPY: TO SCLEROSE OR
TO LIGATE?
EIS has been widely used to arrest AEVH for more
than 30 years [60–63]. The mechanisms of EIS in the
control of AEVH are mainly achieved by inducing
thrombosis of the bleeding varices with a sclerosant.
The sclerosants used in this acute clinical setting
include ethamoline, sotradecol, polidocanol, and alco-
hol. EIS is easy to administer and offers a highly effec-
tive hemostatic rate. Before the advent of EVL, EIS
was the most widely used endoscopic therapy for the
management of AEVH. The hemostatic rate achieved
by emergency EIS ranged from 60% to 100%. Emer-
gency EIS has been compared with vasopressin, 
terlipressin, octreotide, somatostatin, and balloon
tamponade [64]. A meta-analysis of six trials compar-
ing EIS with vasopressin or terlipressin showed a sig-
nificant advantage of EIS in controlling bleeding.
However, the difference in controlling of bleeding
was not significant between EIS and somatostatin 
or octreotide [64]. Of note, EIS was associated with
more complications than the vasoconstrictors. An-
other meta-analysis comparing EIS with vaso-
constrictors in the control of esophageal variceal
hemorrhage also confirmed this trend [53]. Thus, 
it has been suggested that vasoconstrictors could
replace EIS as the first-line treatment for AEVH [53].
Injection of the tissue adhesive agent histoacryl,
which is widely used to arrest gastric variceal bleed-
ing [65], has also been tested in AEVH with some
success [66]. However, the use of tissue adhesive to
treat AEVH is not common, possibly because of the
difficult and time-consuming techniques, particu-
larly if all esophageal variceal channels are treated in
one session.
In contrast, EVL has been widely used to treat
AEVH since 1986. A small cylinder is attached to the
distal end of the endoscope to hold the varices under
suction before ligating the varices with rubber bands.
The mechanism by which EVL arrests AEVH is through
mechanical strangulation of the bleeding varices.
Active bleeding during endoscopy is a great chal-
lenge for endoscopists. Furthermore, some experts
have claimed that the cylinder attached to endoscope
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may hinder the detection of the site of bleeding when
using EVL during active bleeding.
Several studies have shown equivalent hemosta-
tic rates between EIS and EVL in the control of active
bleeding varices (Table) [67–70]. A meta-analysis of
these studies showed that EVL is as effective as EIS
for controlling of active bleeding varices [71]. How-
ever, only a few patients with active bleeding varices
were included in these studies that focused on the
prevention of variceal rebleeding. We have per-
formed a study specifically aimed at comparing EIS
and EVL for the management of active bleeding
varices. Our trial showed that the hemostatic rate 
at 48 hours achieved by EIS and EVL was 76% and
97%, respectively [56]. Complications were more fre-
quently encountered in patients treated with EIS than
with EVL. Based on these observations, the 2005
Baveno Consensus has suggested that EVL should 
be the first choice of endoscopic treatment in the
management of AEVH [47]. EIS could be used in cases
with rapid bleeding that limits the endoscopist’s
visual field. Only one study has compared EVL and
somatostatin for the control of AEVH and showed
that EVL was superior to somatostatin for controlling
hemorrhage without increased risk of adverse events
(Figure 1) [30].
PREVENTION OF EARLY REBLEEDING
Early rebleeding is generally defined as an episode of
rebleeding that occurs within 6 weeks of the initial
bleed. It is estimated that 40% of episodes of early re-
bleeding occur within 5 days of the initial bleeding,
which leads to a high mortality. Consequently, the
latest Baveno Consensus Conference of Portal Hyper-
tension defined the time frame of 48–120 hours after
the initial bleeding as very early rebleeding [72].
It is generally believed that the administration of a
vasoconstrictor such as terlipressin or somatostatin for
5 days can be used to prevent very early rebleeding.
Previous studies showed that prolonged use of either
terlipressin or somatostatin can significantly reduce the
early rebleeding rate [23,49,51]. However, the require-
ment for vasoconstrictors is doubtful if AEVH is suc-
cessfully controlled by EVL. In fact, our study showed
that, even in cases with active bleeding, the use of
emergency EVL without vasoconstrictors could also
achieve a low incidence of very early rebleeding [56].
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Figure 1. Comparison of ligation and somatostatin for the control of acute esophageal variceal hemorrhage. EVL= endoscopic variceal
ligation; SMT= somatostatin (Adapted with permission from [30]).
Table. Ligation versus sclerotherapy in hemostasis of
active variceal hemorrhage*
Study Ligation Sclerotherapy
Stiegmann et al [67] 12/14 (86) 10/13 (77)
Laine et al [68] 8/9 (89) 8/9 (89)
Gimson et al [69] 19/21 (91) 21/23 (92)
Hou et al [70] 20/20 (100) 14/16 (88)
Lo et al [56] 36/37 (97) 26/34 (76)
Total 95/101 (95) 79/95 (83)
*Data presented as number of positive cases/total cases (%).
Combination of vasoconstrictor and
endoscopic therapy
The mechanisms of hemostasis achieved by vasocon-
strictor and endoscopic therapy are different; thus, it
is logical to combine vasoconstrictor and endoscopic
therapy in the management of AEVH. Most controlled
studies have demonstrated that the combination of a
vasoconstrictor and EIS is more effective than either a
vasoconstrictor or EIS alone [57,59,73]. A meta-analysis
revealed that the combination of a vasoconstrictor
and endoscopic therapy achieved 2-day and 5-day
hemostasis rates of 88% and 77%, respectively, which
were significantly higher than that achieved by endo-
scopic therapy alone (76% and 58%, respectively) [74].
However, the proportion of cases with successful
hemostasis achieved by endoscopic therapy alone
was significantly lower than that reported by most
experts experienced in endoscopic therapy. Most of
these trials were carried out during the era of EIS,
except for one trial that used EVL as the endoscopic
therapy. A recent study conducted in Spain showed
that somatostatin in combination with EVL instead of
EIS significantly improved the efficacy and safety 
of treating AEVH [75]. However, the survival was not
significantly improved in patients treated with com-
bination therapy. Thus, the combination of a vasocon-
strictor and endoscopic therapy for the management
of AEVH is more valuable for patients with active
hemorrhage during endoscopy and for endoscopists
not experienced at endoscopic therapy. Nowadays,
the standard of therapy for AEVH should be a vaso-
constrictor in combination with EVL. The use of a
vasoconstrictor can reduce the incidence of very early
rebleeding. However, the optimal duration of vaso-
constrictor therapy remains to be elucidated.
DO WE NEED ENDOSCOPIC THERAPY?
Previous studies showed that EIS may be associated
with substantial complications. Because vasoconstric-
tors alone showed good efficacy for hemostasis, it
was suggested that endoscopic therapy may not be
needed in patients with no active variceal bleeding
during endoscopic examination [2,53,47]. We have
performed a controlled study aimed at evaluating 
the safety and efficacy of EVL for the management 
of inactive variceal bleeding during endoscopic ther-
apy. Our study showed that patients with inactive
bleeding at endoscopy and who received a combina-
tion of terlipressin infusion for 2 days and EVL had
lower rates of very early rebleeding and treatment
failure than patients treated with terlipressin alone for
5 days. Moreover, the rate of complications was not
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Hematemesis or melena
TIPS or shunt operation
Vasoconstrictor, lactulose, antibiotics
Continue vasoconstrictors for 2–5 d
Resuscitation
No rebleeding
Repeat EVL or EIS
Endoscopy
Rebleeding
EVL/EIS
Success Failure
S-B tube
Success Failure
Prevent rebleeding
Confirmed esophageal variceal bleed
Suspected variceal bleed
Figure 2. Algorithm of treatment for acute esophageal variceal hemorrhage. EVL = endoscopic variceal ligation; EIS = endoscopic
injection sclerotherapy; S-B = Sengstaken-Blakemore; TIPS = transjugular intrahepatic portosystemic stent.
significantly increased in patients who received com-
bination therapy. Thus, it can be concluded that a
vasoconstrictor in combination with EVL remains the
treatment of choice for patients presenting with an
inactive variceal hemorrhage at endoscopy [26].
RESCUE THERAPY FOR PATIENTS WITH
UNSUCCESSFUL INITIAL THERAPY
If the combination of a vasoconstrictor and endoscopic
therapy is unsuccessful, the SB tube tamponade offers
a temporary measure to arrest bleeding. Because the
incidence of rebleeding after removal of the SB tube is
high, a more definitive therapy is usually required. An
alternative endoscopic therapy may be considered. For
example, if initial EVL was unsuccessful, the endo-
scopist could perform EIS using a sclerosant or per-
form endoscopic obturation with cyanoacrylate. If
severe esophageal ulceration with bleeding induced by
the endoscopic therapy is noted, a further session of
endoscopic therapy would be very difficult. Shunt
therapy may be considered in patients with good liver
reserve after unsuccessful medical therapy. On the
other hand, patients with poor liver reserve and unsuc-
cessful medical therapy are not suitable for shunt sur-
gery. Instead, a transjugular intrahepatic portosystemic
stent shunt (TIPS) could be applied in these patients.
However, the prognosis is generally dismal. A recent
study suggested that TIPS should be performed early
in patients with AEVH whose HVPG is > 20 mmHg
because these patients generally do not respond well
to standard therapies [76]. However, TIPS can only
be performed by a few medical centers in Taiwan.
TIPS
Before the introduction of TIPS, devascularization or
shunt operation were the only options available for
patients with AEVH that was not amenable to med-
ical therapies available at the time. Although surgical
procedures are generally effective for hemostasis, 
the associated mortality and morbidity rates limit its
clinical utility. TIPS was developed to treat AEVH
that was unsuccessfully treated using standard med-
ical therapies. Approximately 90% of uncontrollable
AEVH could be arrested by TIPS [77,78]. The mortal-
ity rates range from 27% to 55% in patients receiving
emergency TIPS. TIPS is an invasive procedure with
high risk of hepatic encephalopathy; hence, TIPS
should be reserved for patients after unsuccessful
endoscopic treatment.
PREVENTION OF COMPLICATIONS
The occurrence of AEVH may result in serious com-
plications other than shock per se. As described
above, cirrhotic patients presenting with upper gas-
trointestinal hemorrhage are predisposed to develop
renal function impairments, particularly patients in
shock status. On the other hand, bacterial infections are
frequently associated with cirrhotic patients present-
ing with upper gastrointestinal bleeding. The use of
prophylactic antibiotics in cirrhotic patients with
upper gastrointestinal bleeding was reported to reduce
bacterial infections by 30% and mortality by 9% [79].
A study by Hou et al demonstrated that the use of
prophylactic antibiotics in cirrhotic patients with AEVH
could reduce incidence of rebleeding [80]. A controlled
study suggested that the third-generation cephalo-
sporin is more effective than quinolones in the pre-
vention of bacterial infections in cirrhotic patients
presenting with upper gastrointestinal bleeding [81].
However, cephalosporin is expensive. A study by our
colleagues suggested that first-generation cephalo-
sporin was as effective as quinolones in the prevention
of bacterial infections in cirrhotic patients presenting
with upper gastrointestinal bleeding, but with fewer
complications [82].
CARE OF PATIENTS AFTER HEMOSTASIS
Achieving hemostasis is the most important step to
improve the survival of patients with AEVH. Non-
etheless, the associated complications, other than infec-
tion, should also be prevented as much as possible.
One of the precipitating factors for hepatic enceph-
alopathy is gastrointestinal hemorrhage. Thus, the
prophylactic use of lactulose to clear blood products
present in the gastrointestinal tract is mandatory. Dur-
ing resuscitation, a large volume of fluid including
normal saline, blood and frozen plasma may be trans-
fused. The excessive fluid may result in aggravation
of ascites in patients with significant blood loss dur-
ing AEVH. Thus, intravenous fluids should be mini-
mized once hemostasis and stable vital signs have
been achieved. Diuretics may be required in patients
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who develop ascites. It is unknown whether albumin
infusion is helpful in these patients. The role of plate-
let and frozen plasma transfusion in the management
of AEVH is also unknown. The use of activated re-
combinant factor VII, which corrects prothrombin
time in cirrhotic patients, was found to be ineffective
in decreasing the risk of 5-day hemostatic failure [83].
Twelve hours after EVL has achieved hemostasis, the
patient can commence a liquid diet. This avoids the
need for intravenous fluid and provides nutritional
support.
Conversely, because the frequency of rebleeding
in patients achieving hemostasis is high, the patients
that survive the AEVH should be advised to receive
preventive measures [84]. Patients with poor liver
reserve but survive AEVH may be placed on a wait-
ing list for liver transplantation.
CONCLUSION
AEVH is a medical emergency. Appropriate resusci-
tation, early institution of vasoconstrictors and EVL
and concomitant antibiotic prophylaxis, all are ele-
ments to improve survival. For patients with unsuc-
cessful vasoconstrictor and EVL therapy could be
rescued by EIS, balloon tamponade and TIPS. The
choice of the aforementioned modalities for patients
with treatment failure should be individualized and
based on the individual hospital’s available facilities.
The management of AEVH should include a team
with well-trained hepatologists, endoscopists, radiol-
ogists, surgeons and nurses. Cases with intractable,
difficult-to-manage and very severe variceal hemor-
rhage should be transferred to a medical center with
access to a greater wealth of treatment options to 
better treat these patients. The treatment algorithm of
AEVH is shown in Figure 2.
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急性食道靜脈瘤出血之治療
羅錦河
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急性食道靜脈出血是可怕的門脈高血壓併發症。其治療近年來已經有長足的進步。傳
統的治療包括血管收縮劑和食道氣球壓迫止血。血管收縮劑大約可以控制 80﹪的出
血，所以通常用來作第一線治療。使用血管收縮劑以後，內視鏡療法常被用來止血及
預防早期再出血。綜合分析顯示，在急性食道靜脈瘤出血的治療，使用血管收縮劑合
併內視鏡的療法比單獨使用內視鏡療法優越。食道氣球壓迫止血則可用來緊急控制洶
湧出血的情況。經頸靜脈肝內血管分流術可用於很難控制的急性靜脈瘤出血的病人。
另一方面，除了控制急性靜脈瘤出血之外，在預防細菌感染以及早期靜脈瘤的再出
血，事先使用抗生素被證明是有用的。隨著新治療方法的出現，近年來急性食道靜脈
瘤出血病人的死亡率已經有了顯著的下降。
關鍵詞：急性靜脈出血，結紮法，靜脈曲張注射，血管收縮劑 
（高雄醫誌 2010;26:55–67）
